2019
DOI: 10.1200/jco.18.01575
|View full text |Cite
|
Sign up to set email alerts
|

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Abstract: PURPOSE The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND METHODS A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
205
1
11

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 257 publications
(226 citation statements)
references
References 21 publications
9
205
1
11
Order By: Relevance
“…The superiority of VCB/chemotherapy arm was not demonstrated compared to EBRT alone. Acute toxicity was greater with VCB and chemotherapy though late toxicity was similar between the arms [28]. Based on this limited data, we do not currently recommend the use of adjuvant chemotherapy for LVSI positive, unstaged early endometrial cancer patients.…”
Section: Adjuvant Chemotherapymentioning
confidence: 83%
See 4 more Smart Citations
“…The superiority of VCB/chemotherapy arm was not demonstrated compared to EBRT alone. Acute toxicity was greater with VCB and chemotherapy though late toxicity was similar between the arms [28]. Based on this limited data, we do not currently recommend the use of adjuvant chemotherapy for LVSI positive, unstaged early endometrial cancer patients.…”
Section: Adjuvant Chemotherapymentioning
confidence: 83%
“…The management of early stage high intermediate risk patients have been informed by results for GOG 249. VCB and 3 cycles of chemotherapy were not superior to pelvic RT with significant increase in non-hematologic grade 3 and > toxicities in the VCB and chemotherapy arm (GOG 249) [28]. It will be important to evaluate this trial for late toxicities, particularly in the external beam arm.…”
Section: Adjuvant Management Of Early Stage Endometrial Cancermentioning
confidence: 99%
See 3 more Smart Citations